Journal of Natural Remedies

Open Access Open Access  Restricted Access Subscription Access

Topical Application of Ursolic Acid Cream Ameliorates Imiquimod-induced Plaque Psoriasis in BALB/c Mice


Affiliations
1 Department of Pharmacy, Harare Institute of Technology, Harare - BE 277, Zimbabwe
2 Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu, India
 

The valued studies of alternative psoriasis treatment options are in a much higher need among the Scientific Community. This study aimed to evaluate the anti-psoriatic activity of ursolic acid cream in imiquimod-induced psoriasis in BALB/c mice. The creams containing ursolic acid, a pentacyclic triterpenoid at percentages of 0.1 and 0.2% were formulated. The pH, spreadability, physical characteristics and acute dermal irritation of the cream were assessed. Animals were grouped into five each having 6 animals. Clobetasol, a topical corticosteroid, was used as the standard. One group was used as control and four groups were treated with the formulated imiquimod cream while receiving treatment. Parameters such as skin inflammation severity, ear thickness, plasma level of interleukins (IL)-17, histology of the back of the skin and spleen weight were evaluated. Erythema and scales were scored on a daily basis with the 0.1 and 0.2% ursolic acid cream significantly ameliorating psoriatic-like symptoms in a manner comparable to clobetasol. Imiquimod-induced epidermal hyperplasia and inflammation were inhibited by topical application of ursolic acid as shown by the results of histopathology. Spleens of the positive control group were larger in comparison with the rest of the groups. BALB/c mice treated with ursolic acid creams exhibited a decrease in the plasma levels of cytokines IL-17 when compared to the positive control group. The result of this study provided an insight that topical application of ursolic acid can be a potential treatment for psoriasis.

Keywords

Imiquimod, Inflammation, Interleukin-17, Psoriasis, Ursolic Acid
Font Size

User

Notifications
JOURNAL COVERS
  

  • Thomas PS, Pathology VK. Philadelphia, Pa. Blakiston's son; 2007.

  • Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach, ed. Connecticut: Appleton and Lange. 2014; 4:141-2.

  • Walker R. Clinical pharmacy and therapeutics E-Book. Elsevier Health Sciences; 2011; Oct 24.

  • Hammer GD, McPhee SJ, Education MH, editors. Pathophysiology of disease: an introduction to clinical medicine. McGraw-Hill Education Medical; 2014.

  • Schon MP, Boehncke WH, Brocker EB. Psoriasis: clinical manifestations, pathogenesis and therapeutic perspectives. Discov Med. 2009; 5(27):253-8.

  • Naldi L. Psoriasis and smoking: links and risks. Psoriasis (Auckland, NZ). 2016; 6:65. https://doi.org/10.2147/PTT. S85189

  • Casciano F, Pigatto PD, Secchiero P, Gambari R, Reali E. T cell hierarchy in the pathogenesis of psoriasis and associated cardiovascular comorbidities. Front Immunol. 2018; 9:1390. https://doi.org/10.3389/fimmu.2018.01390

  • Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007; 445(7130):866-73. https://doi.org/10.1038/nature05663

  • Vena GA, Vestita M, Cassano N. Psoriasis and cardiovascular disease. Dermatol. Ther. 2010; 23(2):144-51. https://doi. org/10.1111/j.1529-8019.2010.01308.x

  • Fernandez-Armenteros JM, Gomez-Arbones X, Buti-Soler M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, Martínez-Alonso M, Gari E, Portero-Otín M, SantamariaBabi L, Casanova-Seuma JM. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2019; 33(1):128-35. https:// doi.org/10.1111/jdv.15159

  • Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. CFP. 2017; 63(4):278-85.

  • Afifi T, de Gannes G, Huang C, Zhou Y. Topical therapies for psoriasis: Evidence-based review. CFP. 2005; 51(4):519-25.

  • Kang SY, Yoon SY, Roh DH, Jeon MJ, Seo HS, Uh DK, Kwon YB, Kim HW, Han HJ, Lee HJ, Lee JH. The antiarthritic effect of ursolic acid on zymosan-induced acute inflammation and adjuvant-induced chronic arthritis models. J Pharm Pharmacol. 2008; 60(10):1347-54. https:// doi.org/10.1211/jpp.60.10.0011

  • Murphy BT, MacKinnon SL, Yan X, Hammond GB, Vaisberg AJ, Neto CC. Identification of triterpene hydroxycinnamates with in vitro antitumor activity from whole cranberry fruit (Vaccinium macrocarpon). J Agric Food Chem. 2003; 51(12):3541-5. https://doi.org/10.1021/jf034114g

  • Wozniak L, Skapska S, Marszalek K. Ursolic acid-a pentacyclic triterpenoid with a wide spectrum of pharmacological activities. Molecules. 2015; 20(11):20614- 41. https://doi.org/10.3390/molecules201119721

  • Ikeda Y, Murakami A, Ohigashi H. Ursolic acid: An antiand pro-inflammatory triterpenoid. Mol Nutr Food Res. 2008; 52(1):26-42. https://doi.org/10.1002/mnfr.200700389

  • Liu W, Tan X, Shu L, Sun H, Song J, Jin P, Yu S, Sun M, Jia X. Ursolic acid inhibits cigarette smoke extract-induced human bronchial epithelial cell injury and prevents development of lung cancer. Molecules. 2012; 17(8):9104- 15. https://doi.org/10.3390/molecules17089104

  • Sultana N. Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic acid and related derivatives as medicinally important natural product. J Enzyme Inhib Med Chem. 2011; 26(5):616-42. https://doi.org/10.3109/14 756366.2010.546793

  • Do Nascimento PG, Lemos TL, Bizerra A, Arriaga A, Ferreira DA, Santiago GM, Braz-Filho R, Costa JG. Antibacterial and antioxidant activities of ursolic acid and derivatives. Molecules. 2014; 19(1):1317-27. https://doi. org/10.3390/molecules19011317

  • Jin YR, Jin JL, Li CH, Piao XX, Jin NG. Ursolic acid enhances mouse liver regeneration after partial hepatectomy. Pharm Biol. 2012; 50(4):523-8. https://doi.org/10.3109/13880209.2 011.611143

  • Nema RK, Rathore KS, Dubey BK. Textbook of cosmetics. CBS Publishers and Distributors; 2009.

  • Dhyani A, Chander V, Singh N. Formulation and evaluation of multipurpose herbal cream. J Drug Deliv Ther. 2019; 9(2):341-3. https://doi.org/10.22270/jddt.v9i2.2540

  • OECD Guideline: OECD 404.

  • Sun J, Zhao Y, Hu J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PloS one. 2013; 8(6):e67078. https:// doi.org/10.1371/journal.pone.0067078

  • Dou R, Liu Z, Yuan X, Xiangfei D, Bai R, Bi Z, Yang P, Yang Y, Dong Y, Su W, Li D. PAMs ameliorates the imiquimodinduced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines. PLoS One. 2017; 12(5):e0176823. https://doi. org/10.1371/journal.pone.0176823

  • Zhao J, Di T, Wang Y, Wang Y, Liu X, Liang D, Li P. Paeoniflorin inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response and cytokine secretion. Eur J Pharmacol. 2016; 772:131-43. https://doi.org/10.1016/j. ejphar.2015.12.040

  • Chen YH, Wu CS, Chao YH, Lin CC, Tsai HY, Li YR, Chen YZ, Tsai WH, Chen YK. Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice. J Food Drug Anal. 2017; 25(3):559-66. https://doi. org/10.1016/j.jfda.2016.06.003

  • Kuchekar S, Bhise K. Formulation and development of antipsoriatic herbal gelcream. J Sci Ind Res. 2012; 71(4):279- 284.

  • Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G, Nestle FO, Dummer R. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004; 140(12):1490-5. https://doi.org/10.1001/ archderm.140.12.1490

  • Van Der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009; 182(9):5836-45. https://doi.org/10.4049/ jimmunol.0802999

  • Sonja Moos, Alma N Mohebiany, Ari Waisman Florian C. Kurschus. Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. J Invest Dermatol. 2019; 139(5):1110-1117. https://doi.org/10.1016/j. jid.2019.01.006

  • Thaci D, Humeniuk J, Frambach Y, Bissonnette R, Goodman JJ, Shevade S, Gong Y, Papavassilis C, STATURE Study Group. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). British Journal of Dermatology. 2015; 173(3):777-87. https://doi.org/10.1111/bjd.13814


Abstract Views: 111

PDF Views: 79




  • Topical Application of Ursolic Acid Cream Ameliorates Imiquimod-induced Plaque Psoriasis in BALB/c Mice

Abstract Views: 111  |  PDF Views: 79

Authors

Precious Derera
Department of Pharmacy, Harare Institute of Technology, Harare - BE 277, Zimbabwe
M. Sumithra
Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu, India
V. Chitra
Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu, India
R. Mrinalini
Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu, India
Rukaiah Fatma Begum
Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur - 603203, Tamil Nadu, India

Abstract


The valued studies of alternative psoriasis treatment options are in a much higher need among the Scientific Community. This study aimed to evaluate the anti-psoriatic activity of ursolic acid cream in imiquimod-induced psoriasis in BALB/c mice. The creams containing ursolic acid, a pentacyclic triterpenoid at percentages of 0.1 and 0.2% were formulated. The pH, spreadability, physical characteristics and acute dermal irritation of the cream were assessed. Animals were grouped into five each having 6 animals. Clobetasol, a topical corticosteroid, was used as the standard. One group was used as control and four groups were treated with the formulated imiquimod cream while receiving treatment. Parameters such as skin inflammation severity, ear thickness, plasma level of interleukins (IL)-17, histology of the back of the skin and spleen weight were evaluated. Erythema and scales were scored on a daily basis with the 0.1 and 0.2% ursolic acid cream significantly ameliorating psoriatic-like symptoms in a manner comparable to clobetasol. Imiquimod-induced epidermal hyperplasia and inflammation were inhibited by topical application of ursolic acid as shown by the results of histopathology. Spleens of the positive control group were larger in comparison with the rest of the groups. BALB/c mice treated with ursolic acid creams exhibited a decrease in the plasma levels of cytokines IL-17 when compared to the positive control group. The result of this study provided an insight that topical application of ursolic acid can be a potential treatment for psoriasis.

Keywords


Imiquimod, Inflammation, Interleukin-17, Psoriasis, Ursolic Acid

References





DOI: https://doi.org/10.18311/jnr%2F2023%2F29734